Prime Medicine Inc. is a clinical-stage biotechnology company specializing in genetic therapies based on its proprietary Prime Editing platform. The company focuses on developing one-time genetic treatments that precisely modify DNA to address the underlying causes of disease. Prime Medicine’s Prime Editing technology combines engineered Prime Editor proteins with specialized guide RNAs to “search and replace” targeted DNA sequences, enabling corrections, insertions, or deletions without creating double-stranded breaks in the genome. Today, Prime Medicine is advancing a diversified pipeline of investigational therapies across hematology, immunology and oncology, as well as liver and lung indications, with an emphasis on rare and severe genetic disorders and diseases with clearly defined biology. Operating as a single, research-driven segment, the company generates value through discovery, preclinical and clinical development of prime editing-based candidates, and collaborations with other biopharmaceutical firms in areas such as cell therapies and shielded-cell immunotherapies. Founded in 2019 and headquartered in Cambridge, Massachusetts, Prime Medicine occupies a prominent position in the emerging gene editing and genetic medicines sector.